Welcome to our dedicated page for I-Mab news (Ticker: IMAB), a resource for investors and traders seeking the latest updates and insights on I-Mab stock.
I-Mab (NASDAQ: IMAB), now known as NovaBridge Biosciences, generates a steady flow of news as a U.S.-based, global biotech company focused on precision immuno-oncology. Investors following IMAB-related headlines can track how the company advances its lead Claudin 18.2 x 4-1BB bispecific antibody, givastomig, and other pipeline assets through clinical milestones, strategic transactions, and capital markets activity.
News coverage commonly highlights clinical data from Phase 1 and Phase 1b studies of givastomig in Claudin 18.2-positive gastric and gastroesophageal cancers, including monotherapy results and combination regimens with immunochemotherapy in the first-line metastatic setting. Company announcements describe objective response rates, safety findings, and study design details from presentations at major oncology conferences such as ESMO GI and the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics meeting.
Beyond clinical readouts, IMAB news items also cover the company’s broader transformation into a global biotech platform under the NovaBridge Biosciences name. Releases discuss the adoption of a hub-and-spoke business model, the formation of subsidiaries like Visara, Inc. for VIS-101 in ophthalmology, and strategic agreements with partners including ABL Bio, AffaMed Therapeutics, AskGene Pharma, and Everest Medicines. Capital markets updates, such as underwritten offerings of American Depositary Shares and intentions to pursue a dual listing on the Hong Kong Stock Exchange, are also key themes.
On this news page, readers can review company press releases, SEC-referenced announcements, and other IMAB-related updates in one place. For investors and researchers, regularly checking this feed offers insight into clinical progress, partnership activity, governance changes, and financing events that shape the outlook for I-Mab’s, and NovaBridge Biosciences’, oncology and ophthalmology programs.
I-Mab (Nasdaq: IMAB) has advanced its 4-1BB bispecific antibody portfolio, initiating a U.S. phase 1 clinical trial for TJ-CD4B/ABL111 in patients with advanced solid tumors, with the first dose administered on June 29, 2021. Chinese sites will join to expedite the study, targeting patients with gastric, esophageal, and pancreatic cancers. Additionally, preclinical results for TJ-L14B/ABL503 have been accepted for publication, showcasing superior anti-tumor activity. These developments promise to enhance immunotherapy strategies in oncology.
I-Mab (Nasdaq: IMAB) has been recognized in the "Honored Companies" and "Best CFO" categories by Institutional Investor's 2021 All-Asia Executive Team survey, highlighting its commitment to innovation and financial management. Since its IPO in 2020, I-Mab has achieved key clinical milestones, maintaining over $6 billion in market capitalization. The company’s pipeline includes 16 assets, with 11 in clinical development. Recently, it raised $418 million in one of the largest PIPE financings and has been added to over 50 global indexes, underscoring its strong market presence.
I-Mab (Nasdaq: IMAB), a clinical stage biopharmaceutical company, announced its participation in the CMBI Healthcare Corporate Day virtual conference scheduled for July 7-9, 2021. Key executives, including Dr. Jingwu Zang and Dr. Joan Huaqiong Shen, will partake in one-on-one and small group meetings with attendees. I-Mab is focused on developing novel immuno-oncology therapeutics and has a robust pipeline of over 15 clinical and pre-clinical candidates. The company is progressing towards becoming a fully integrated global biopharmaceutical firm with substantial R&D and manufacturing capabilities.
I-Mab (NASDAQ: IMAB) has received approval from the China National Medical Products Administration for its IND application to begin a phase 1b trial of felzartamab, a CD38 antibody, in patients with systemic lupus erythematosus. This multi-center study aims to assess the drug's safety, tolerability, pharmacokinetics, and pharmacodynamics. Felzartamab targets dysregulated CD38-positive B cells, addressing a significant unmet need in SLE treatment. I-Mab is also pursuing registration trials for felzartamab in multiple myeloma across Greater China.
I-Mab (Nasdaq: IMAB) announced the appointment of Andrew Zhu, MD, PhD, to its Scientific Advisory Board. Dr. Zhu is a recognized expert in hepatobiliary cancers and has held key positions at Harvard Medical School and Massachusetts General Hospital. His experience is expected to enhance I-Mab's ongoing development of novel immuno-oncology therapies. This strategic move aligns with the company's mission to innovate in drug development and expand its clinical capabilities, potentially bolstering its competitive position in the biopharmaceutical industry.
I-Mab (Nasdaq: IMAB) announced an investor call on June 7, 2021, to discuss in-depth clinical data from its U.S. phase 1 study of uliledlimab in combination with atezolizumab (TECENTRIQ®) for treating advanced cancers. Uliledlimab, a humanized antibody targeting CD73, aims to enhance anti-tumor immune responses and has shown promising preclinical results. The company is transitioning from clinical development to becoming a fully integrated global biopharmaceutical entity with a robust pipeline of over 15 drug candidates.
I-Mab (Nasdaq: IMAB) has announced the election of Dr. Ruyi He and Professor Rong Shao to its board of directors, effective June 1, 2021. Dr. He, a former Chief Scientist at China's NMPA and current Chief Medical Officer at RemeGen Inc, brings extensive experience in drug evaluation and international policy implementation. Professor Shao is a leading expert in drug administration policies, holding roles at China Pharmaceutical University. Their appointments aim to enhance I-Mab’s strategic growth in the biopharmaceutical sector and bolster its transition into a fully integrated global company.
I-Mab (Nasdaq: IMAB) announced its participation in several upcoming healthcare conferences in June 2021. Key events include the Jefferies Healthcare Conference on June 1 and various one-on-one meetings from June 2-4 and June 7-10. Notably, Dr. Joan Huaqiong Shen will present at the Haitong Annual Investor Conference on June 16. The company aims to advance its mission of developing innovative biologics in immuno-oncology, boasting a robust pipeline of over 15 clinical and pre-clinical candidates.
I-Mab announced promising results from a Phase 1 trial of uliledlimab, a novel CD73 antibody, in combination with atezolizumab for advanced cancer patients. The study reported favorable safety and tolerability, with no dose-limiting toxicities. Out of 13 efficacy-evaluable patients, 23% had complete or partial responses, while 46% showed stable disease. The U.S. trial data will be presented at ASCO 2021, where the abstract was selected as one of the Top 12 for poster discussion. I-Mab will host an investor call on June 7, 2021, to discuss the findings.
I-Mab (Nasdaq: IMAB) announced the initiation of a phase 2 combination trial for lemzoparlimab with azacitidine in newly diagnosed Acute Myeloid Leukemia (AML) patients in China. This trial aligns with an accelerated development plan targeting NDA approval for hematologic malignancies. Preliminary results from ongoing U.S. cohort studies in non-Hodgkin lymphoma and advanced solid tumors are expected by early 2022. Lemzoparlimab is a next-gen anti-CD47 monoclonal antibody, designed to improve anti-tumor activity while reducing anemia risk.